Sanifit Presents Results of SNF472 for the Treatment of Vascular Calcification at ASN Kidney Week 2020

 Sanifit Presents Results of SNF472 for the Treatment of Vascular Calcification at ASN Kidney Week 2020

Sanifit Presents Results of SNF472 for the Treatment of Vascular Calcification at ASN Kidney Week 2020

Shots:

  • The additional insight from the P-IIb CaLIPSO study showed that SNF472 slowed the progression of CAC across key subgroups of patients on hemodialysis participating in the study. The presentation highlights the PK/PD and exposure-response analyses
  • Sanifit also presents the design of its ongoing P-III CALCIPHYX study evaluating the efficacy and safety of SNF472 for the treatment of patients with calciphylaxis (calcific uremic arteriolopathy, or CUA). Additional data demonstrated that SNF472 strongly inhibits valvular calcification in an in vitro model of porcine aortic valve
  • SNF472 is an inhibitor of vascular calcification currently in P-III study, acts by targeting the deposition of solid calcium (hydroxyapatite, HAP) in the CV system. The company is showcasing new data on SNF472 in four presentations including one oral session and three ePoster sessions at virtual ASN Kidney Week 2020

Click here ­to­ read full press release/ article | Ref: Sanifit | Image: European Biotechnology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post